Full-Time

Senior Manager

Internal Communications

Posted on 7/15/2024

Biorender

Biorender

201-500 employees

Online platform for scientific illustrations

Mid, Senior

Toronto, ON, Canada

Hybrid model with a physical office in Toronto.

Category
Human Resources
People & HR
Required Skills
Communications
Requirements
  • 4+ years of experience leading internal communications within fast-paced, remote tech company environment
  • Strong track record of partnering with founders and/or senior executives with examples of influencing stakeholders and adapting work various work styles
  • Strong storyteller, able to articulate complex ideas to different audiences
  • Experience tracking metrics and analyzing feedback to continuously improve communication strategies
  • Familiarity with our communication channels: Zoom/Meets, Slack and Notion
  • Resilience and grit—able to maintain a proactive, even-keeled approach when faced with rapid organizational change and shifting priorities.
  • Able to think and do—you can both generate ideas and implement them.
Responsibilities
  • Build and implement an integrated employee communications strategy that helps employees understand our business and feel connected to our culture
  • Cascade communication from the executive team through live (e.g. all-hands) and async (e.g. wiki, slack) options
  • Enable effective change management through targeted communications that help employees understand changes within the overall business context
  • Scale our remote culture as we grow through creative internal events and communication channels.

BioRender provides an online platform for creating scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates across more than 30 life sciences fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform's user-friendly interface enables clients, including academic researchers, pharmaceutical companies, and educational institutions, to create figures for research papers, presentations, and educational materials with minimal effort. BioRender operates on a subscription model, offering various plans that cater to different user needs, including enterprise solutions for larger organizations. The company's goal is to simplify the process of creating high-quality scientific illustrations, making it an essential resource for effective scientific communication.

Company Size

201-500

Company Stage

Series A

Total Funding

$16.7M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for digital communication boosts need for scientific visualization tools.
  • Growing interest in graphical abstracts enhances research visibility and accessibility.
  • Open-access publishing trend increases demand for high-quality, appealing figures.

What critics are saying

  • AI-driven design tools may reduce demand for BioRender's platform.
  • Increased competition from cheaper visualization platforms could erode market share.
  • Potential IP disputes over pre-drawn icons could lead to legal challenges.

What makes Biorender unique

  • BioRender offers a vast library of customizable icons and templates for scientists.
  • The platform provides a user-friendly interface for creating professional scientific figures.
  • BioRender serves diverse clients, including academia, biotech, and pharmaceutical companies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

3%

2 year growth

5%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.

INACTIVE